Screening, risk assessment, and the approach to therapy in patients with prostate cancer (Q37801615)

23 August 2017

Screening, risk assessment, and the approach to therapy in patients with prostate cancer (English)

1 reference

23 August 2017

0 references

1 reference

Stephen J Freedland

1

1 reference

PubMed ID

20960523

23 August 2017

language of work or name

English

0 references

publication date

19 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

117

1 reference

23 August 2017

6

1 reference

23 August 2017

1123-1135

1 reference

23 August 2017

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Estimates of the cancer incidence and mortality in Europe in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

The global state of prostate cancer: epidemiology and screening in the second millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Biology of prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Effect of Inflammation and Benign Prostatic Hyperplasia on Elevated Serum Prostate Specific Antigen Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Effect of ejaculation on serum total and free prostate-specific antigen concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Biomarkers for prostate cancer detection and progression: Beyond prostate-specific antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Screening for prostate cancer--the controversy that refuses to die.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

The role of primary androgen deprivation therapy in localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Delayed versus immediate surgical intervention and prostate cancer outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Active surveillance for early-stage prostate cancer: review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Prostate cryotherapy: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Critical appraisal of outcomes following open radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Prostate specific antigen recurrence after definitive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Percent tumor involvement and risk of biochemical progression after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Effect of DNA methylation on identification of aggressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Predictors of metastatic disease in men with biochemical failure following radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Optimal timing of chemotherapy in androgen independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

The role of systemic cytotoxic therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened P

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Predicting Unilateral Prostate Cancer Based on Biopsy Features: Implications for Focal Ablative Therapy—Results From the SEARCH Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

A meta-analysis of the performance characteristics of the free prostate-specific antigen test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

EAU guidelines on prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Clinical states in prostate cancer: toward a dynamic model of disease progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Prostate-specific antigen velocity and prostate cancer gleason grade and stage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Hepatic resection: the last surgical frontier for colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25477

7 January 2021

Identifiers

DOI

10.1002/CNCR.25477

1 reference

23 August 2017

1 reference

PubMed ID

20960523